http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#Head
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#assertion
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#provenance
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#pubinfo
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#assertion
http://purl.obolibrary.org/obo/DOID_2957
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_2957
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB01201
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#association
http://www.w3.org/2000/01/rdf-schema#label
priftin is a rifamycin antimycobacterial drug indicated in patients 12 years of age and older for the treatment of active pulmonary tuberculosis tb caused by mycobacterium tuberculosis 1 1 priftin is indicated for the treatment of latent tuberculosis infection ltbi caused by m tuberculosis 1 2 see limitations of use 1 1 1 2 priftin a r mycobacterium tuberculosis see dosage and administration 2 1 clinical studies 14 1 limitations of use do not use priftin monotherapy in either the initial or the continuation phases of active antituberculous treatment priftin should not be used once weekly in the continuation phase regimen in combination with isoniazid inh in hiv infected patients with active pulmonary tuberculosis because of a higher rate of failure and or relapse with rifampin rif resistant organisms see warnings and precautions 5 3 clinical studies 14 1 priftin has not been studied as part of the initial phase treatment regimen in hiv infected patients with active pulmonary tuberculosis priftin is indicated in adults and children 2 years and older for the treatment of latent tuberculosis infection caused by mycobacterium tuberculosis see clinical studies 14 2 limitations of use active tuberculosis disease should be ruled out before initiating treatment for latent tuberculosis infection priftin must always be used in combination with isoniazid as a 12 week once weekly regimen for the treatment of latent tuberculosis infection see dosage and administration 2 2 clinical studies 14 2 priftin in combination with isoniazid is not recommended for individuals presumed to be exposed to rifamycin resistant or isoniazid resistant m tuberculosis
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB01201
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#provenance
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#pubinfo
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#sig
http://purl.org/nanopub/x/hasSignature
VTVI7yu9OWKoJQDQjcgQY8jJFcf4O7t7U6uCiU03UcoawzLSSwmO08DqI1VpNfBErzbywalgMG9oYs0USK+Qlw2a8ixon91qPELHb0kWivG0Z3wc8JFt8DFr7Idze/yRYZvTHJ57y3swmp9rxl46VR8NdkhhpggUDtuy2mT6k4Q=
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc
http://purl.org/dc/terms/created
2021-06-15T18:15:57.113+02:00
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAKJ3r8SnBtNBpKSzLprO8vqnAS4dQSwruHhviJZehiWc
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs